2020
Medical marijuana certification for patients with sickle cell disease: a report of a single center experience
Curtis SA, Lew D, Spodick J, Hendrickson JE, Minniti CP, Roberts JD. Medical marijuana certification for patients with sickle cell disease: a report of a single center experience. Blood Advances 2020, 4: 3814-3821. PMID: 32790846, PMCID: PMC7448584, DOI: 10.1182/bloodadvances.2020002325.Peer-Reviewed Original ResearchConceptsOpioid useMedical marijuanaSickle cell disease (SCD) reportBaseline opioid useSingle-center experienceHealth care utilizationSickle cell diseaseOpioid utilizationClinical characteristicsMost patientsCenter experienceCare utilizationSCD patientsInpatient hospitalizationRandom patientsAdmission ratesCell diseasePatientsRetrospective dataDisease reportsStudy periodHealth careCannabis productsCannabisEdible cannabis products
2018
Medical Marijuana for Sickle Cell Disease: Results of Two Years of Certification in an Adult Sickle Cell Center
Curtis S, Lew D, Spodick J, Roberts J. Medical Marijuana for Sickle Cell Disease: Results of Two Years of Certification in an Adult Sickle Cell Center. Blood 2018, 132: 858. DOI: 10.1182/blood-2018-99-118290.Peer-Reviewed Original ResearchSickle cell diseaseAcute service utilizationOral morphine equivalentsPrevious marijuana useOpioid useDaily opioid useService utilizationHospital admissionAdmission ratesHydroxyurea useChronic painInsurance typeAcute servicesCell diseaseAcute care service utilizationTotal oral morphine equivalentsBaseline opioid useRegular clinic visitsPrescription monitoring programsMarijuana useSickle Cell CenterOnly clinical differenceQuality of lifeT-testElectronic medical records